Arcellx, Inc. ACLX announced that the first patient has been dosed in its open-label, multi centre phase 1 clinical study of ACLX-001 for patients with Relapsed or Refractory Multiple Myeloma (r/r MM).

The Phase 1 clinical trial is currently evaluating the novel ARC-SparX program in patients with relapsed or refractory multiple myeloma

Rami Elghandour, Chairman and CEO, said, “Our ARC-SparX platform, powered by our proprietary D-Domain technology, has the potential to yield transformative therapies that can unleash the full potential of CAR-Ts to treat challenging conditions, including solid tumors. By addressing antigen heterogeneity and dose limiting toxicities, ARC-SparX could help many patients and address significant unmet clinical needs.”

The company is planning to enrol additional patients in this study.

Initial data readout from the ACLX-001 Phase 1 study is anticipated in 2023.

Arcellx closed regular trading up 14 percent at $9.69.